Glaxo and the Making of a Blockbuster Drug

Centient Biotech Investor submits: GlaxoSmithKline announced results yesterday. As expected, there was plenty of good news. Sales are brisk. Profit was up 5%. And among those numbers was a once little known drug, called Requip, that is now performing spectacularly well.
From: biz.yahoo.com